Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Research & Development (2016 - 2025)

United Therapeutics' Research & Development history spans 17 years, with the latest figure at $139.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 4.26% year-over-year to $139.5 million; the TTM value through Dec 2025 reached $550.0 million, up 14.35%, while the annual FY2025 figure was $550.0 million, 14.35% up from the prior year.
  • Research & Development for Q4 2025 was $139.5 million at United Therapeutics, up from $127.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $303.7 million in Q1 2021 and bottomed at $66.1 million in Q3 2022.
  • The 5-year median for Research & Development is $98.7 million (2022), against an average of $115.1 million.
  • The largest annual shift saw Research & Development surged 314.89% in 2021 before it plummeted 77.28% in 2022.
  • A 5-year view of Research & Development shows it stood at $82.9 million in 2021, then increased by 13.27% to $93.9 million in 2022, then surged by 61.24% to $151.4 million in 2023, then decreased by 11.62% to $133.8 million in 2024, then rose by 4.26% to $139.5 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Research & Development are $139.5 million (Q4 2025), $127.5 million (Q3 2025), and $134.0 million (Q2 2025).